Publications by authors named "Peter Steen Hansen"
Article Synopsis
- Pulsed field ablation (PFA) is a new method for treating atrial fibrillation (AF) that focuses on ablating heart tissue while minimizing harm to nearby structures.
- In the MANIFEST-17K study, data from 106 centers involved 17,642 patients and showed no serious complications like esophageal damage, with only a 1% major complication rate.
- The results suggest that PFA has a strong safety profile and may change how AF is treated, compared to traditional thermal ablation methods.
Article Synopsis
- The study aimed to validate the National Danish Ablation Database (NDAD) by comparing its data on patients who underwent ablation for atrial fibrillation against their medical records.
- Researchers included 597 patients and assessed positive predictive values (PPV) and negative predictive values (NPV) across different categories, finding high agreement with both PPV and NPV exceeding 90%.
- Results indicated that NDAD has strong validity, with data aligning well with medical records, although the low complication rates led to slightly less certainty in the PPV and NPV related to complications.
Periprocedural complications and one-year outcomes after catheter ablation for treatment of atrial fibrillation in elderly patients: a nationwide Danish cohort study.
Jesper Nielsen Kristian Hay Kragholm Sofie Brix Christensen Arne Johannessen Christian Torp-Pedersen Peter Steen Hansen
J Geriatr Cardiol
November 2021
Article Synopsis
- The study examined complications within 30 days of first-time catheter ablation for atrial fibrillation (AF) in patients aged ≥ 75 years compared to those aged 65-74 years.
- No significant difference in the rate of complications, including cardiac issues and death, was found between the two age groups, indicating similar safety profiles.
- Additionally, there was no notable difference in one-year AF relapse rates, suggesting that older patients do not face higher risks or reduced effectiveness from the procedure compared to younger patients.
Article Synopsis
- Oral anticoagulation (OAC) is recommended for patients with atrial fibrillation (AF) and atrial flutter (AFL) who have higher CHADS-VASc scores, even after catheter ablation.
- A study analyzed 2,409 patients who underwent cavo-tricuspid isthmus ablation (CTIA) for AFL, revealing that 30% of them discontinued OAC during a follow-up period of about 4 years.
- Findings indicated younger patients with fewer health issues were more likely to stop OAC, but those who did face increased risks of mortality and stroke, especially correlated with older age and higher CHADS-VASc scores.
Recurrent atrial flutter ablation and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: A nation-wide Danish cohort study.
Mikkel Giehm-Reese Mads Brix Kronborg Peter Lukac Steen Buus Kristiansen Jan Møller Nielsen Peter Steen Hansen
Int J Cardiol
January 2020
Article Synopsis
- Cavo tricuspid isthmus ablation (CTIA) is an effective treatment for typical atrial flutter (AFL), but many patients develop atrial fibrillation (AF) afterward.
- A study analyzed data from 2409 patients in the Danish National Ablation Registry who underwent first-time CTIA between 2010 and 2016, following their outcomes until 2018.
- Findings revealed that 10% of the patients needed a re-ablation for AFL and 13.5% underwent ablation for AF over an average follow-up of 4 years, with younger patients and those with fewer health issues being more likely to require additional procedures.
Article Synopsis
- The study investigates the impact of atrial fibrillation (AF) on symptoms and health-related quality of life (HRQoL) among a large group of patients in Scandinavia, focusing on gender and age differences.
- Results show women report more symptoms and have a greater negative impact on HRQoL, while older patients mainly experienced more negative influences in specific areas.
- The findings highlight the importance of considering gender-related differences in care and management of AF, emphasizing the need for gender-specific patient-reported outcomes measures.
Impact of Substrate Modification by Catheter Ablation on Implantable Cardioverter-Defibrillator Interventions in Patients With Unstable Ventricular Arrhythmias and Coronary Artery Disease: Results From the Multicenter Randomized Controlled SMS (Substrate Modification Study).
Karl-Heinz Kuck Roland Richard Tilz Thomas Deneke Boris A Hoffmann Rodolfo Ventura Peter Steen Hansen
Circ Arrhythm Electrophysiol
March 2017
Article Synopsis
- The implantable cardioverter-defibrillator (ICD) is the primary treatment for preventing sudden cardiac death in patients with coronary artery disease and serious heart rhythm issues, and the Substrate Modification Study (SMS) looked at whether preemptively ablating heart tissue could reduce the recurrence of dangerous arrhythmias.
- In a study of 111 patients, those who received catheter ablation in addition to ICD implantation showed a similar rate of first arrhythmia recurrence compared to those who only had the ICD, measured over an average follow-up of 2.3 years.
- Although the SMS didn't achieve its main goal regarding first recurrence, it did find that catheter ablation led to fewer overall ICD interventions during the follow-up period.
Article Synopsis
- - The MANTRA-PAF trial compared the effectiveness of radiofrequency catheter ablation (RFA) versus antiarrhythmic drug therapy (AAD) for treating paroxysmal atrial fibrillation (AF), measuring outcomes over a 5-year follow-up.
- - Results showed that a higher percentage of patients in the RFA group remained free of AF (86% vs 71%) and symptomatic AF (94% vs 85%) compared to those receiving AAD, with significant differences in AF burden as well.
- - Quality of life scores improved for both groups from baseline, but there were no significant differences between the RFA and AAD groups at the 5-year mark.
Article Synopsis
- The study aimed to evaluate the safety of catheter ablation for atrial fibrillation (AF) in patients using novel oral anticoagulants (NOAC) as part of a simple anticoagulation protocol.
- A total of 234 patients on NOACs were included, with no major bleeding or thromboembolic complications observed during the procedure or follow-up, except for one minor case.
- The findings suggest that temporarily stopping NOACs before the procedure, without the use of bridging therapy like low molecular weight heparin, is safe and well-tolerated for patients undergoing AF ablation.
Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial.
M J Pekka Raatikainen Antti Hakalahti Paavo Uusimaa Jens Cosedis Nielsen Arne Johannessen Peter Steen Hansen
Int J Cardiol
November 2015
Article Synopsis
- The MANTRA-PAF study compares the effectiveness of radiofrequency catheter ablation (RFA) to antiarrhythmic drugs (AADs) for treating paroxysmal atrial fibrillation (PAF) as first-line therapy.
- The results showed that, after 24 months, patients in the RFA group had significantly lower AF burden and a higher percentage of being free from AF compared to those using AADs and those who crossed over to other treatments.
- Quality of life improved across all treatment groups with no significant differences in serious adverse events, suggesting that RFA could be a better first-line option for symptomatic PAF patients.
Article Synopsis
- A study assessed Danish cardiologists' attitudes toward catheter ablation for atrial fibrillation (AF) using a nationwide survey, finding a significant response rate of 67.8%.
- The results indicated that the majority of cardiologists anticipate AF recurrence post-ablation, with a more favorable view of the procedure correlated with the cardiologist's age and experience, especially for longstanding AF cases.
- Overall, Danish cardiologists hold a generally positive stance towards catheter ablation for AF and are informed about appropriate patient information regarding the treatment options.
Article Synopsis
- The study aimed to compare the cost-effectiveness of radiofrequency catheter ablation (RFA) versus antiarrhythmic drugs (AADs) for treating paroxysmal atrial fibrillation (AF) as a first-line treatment.
- Utilizing a Markov model based on the MANTRA-PAF study, results showed RFA provided a small clinical benefit at an incremental cost-effectiveness ratio of €50,570 per quality-adjusted life year (QALY) overall.
- However, RFA was identified as more cost-effective in patients aged 50 and younger (€3,434/QALY), while the cost-effectiveness in older patients was less favorable, suggesting AADs may be the better first
Article Synopsis
- New non-drug treatments for atrial fibrillation have emerged, focusing on prevention and symptom relief.
- Radiofrequency ablation (RFA) has been a treatment option in Denmark since 2001, with 2,529 procedures done in 2011.
- RFA is favored by young patients or those who don't respond to medication, targeting the source of irregular heartbeats from the pulmonary veins.
Article Synopsis
- A study compared the effectiveness of radiofrequency catheter ablation and antiarrhythmic drug therapy for treating patients with paroxysmal atrial fibrillation by randomly assigning 294 patients to one of the two treatment strategies.
- Results showed that while there was no significant difference in the overall burden of atrial fibrillation between the two groups at various follow-up points, the ablation group had a notably lower burden at 24 months and a higher rate of patients free from atrial fibrillation.
- Despite these findings, there were some complications in the ablation group, and a significant number of patients in the drug therapy group later required additional ablation procedures.
Article Synopsis
- The study aimed to assess the recurrence of atrial fibrillation (AF) and flutter (AFL) after a specific treatment called circumferential pulmonary vein ablation (CPVA), using long-term Holter monitoring and analyzing quality of life (QoL).
- 149 patients were monitored with 7-day Holter recordings for up to 12 months post-CPVA, categorizing their arrhythmia episodes and using SF-36 questionnaires to evaluate QoL changes in relation to symptom presence.
- Results showed that 44% of patients had asymptomatic arrhythmia after a year, with a notable improvement in the QoL physical scores for those with asymptomatic recurrences compared to those who were symptomatic, indicating the need
Article Synopsis
- The MANTRA-PAF trial is a large randomized study comparing the effectiveness of radiofrequency ablation (RFA) versus anti-arrhythmic drug (AAD) therapy for treating paroxysmal atrial fibrillation (AF).
- The trial aims to assess the primary outcome of AF relapse over 24 months and also looks at various secondary outcomes like hospitalization rates and quality of life.
- Enrolment began in 2005, with 260 patients enrolled by November 2008, and the study aims to finalize recruitment with 300 patients by March 2009.
Article Synopsis
- Chronic arrhythmias can lead to cardiomyopathy, which is a disease of the heart muscle.
- The text discusses two young men who experienced severe cardiomyopathy due to frequent monomorphic ventricular ectopy, a type of irregular heartbeat.
- Treatment through radiofrequency ablation of the ectopic focus in the left ventricle successfully restored normal heart function in both cases within a few months.
DDD(R)-pacing, but not AAI(R)-pacing induces left ventricular desynchronization in patients with sick sinus syndrome: tissue-Doppler and 3D echocardiographic evaluation in a randomized controlled comparison.
Andi Eie Albertsen Jens Cosedis Nielsen Steen Hvitfeldt Poulsen Peter Thomas Mortensen Anders Kirstein Pedersen Peter Steen Hansen
Europace
February 2008
Article Synopsis
- The study investigates the effects of right ventricular (RV) pacing on heart function in 50 patients with sick sinus syndrome, comparing atrial pacing (AAI(R)) and dual chamber RV-pacing (DDD(R)).
- Results showed that DDD(R)-pacing resulted in increased left ventricular (LV) dyssynchrony and a significant decrease in LV ejection fraction (LVEF) over 12 months, while AAI(R)-pacing did not show these changes.
- The conclusion emphasizes that DDD(R)-pacing leads to notable LV desynchronization and decline in heart function, which is not seen with AAI(R)-pacing in these patients.
Article Synopsis
- The study compares two main methods of radiofrequency ablation for treating atrial fibrillation: segmental pulmonary vein isolation (SPVI) and circumferential pulmonary vein isolation (CPVI).
- Results show that 73% of patients were symptom-free after CPVI, while only 25% were symptom-free after SPVI.
- The findings suggest that CPVI is a safer and more effective treatment for patients with severe symptoms and drug-resistant AF when performed by experienced specialists.
Article Synopsis
- The study focuses on the effectiveness of cardiac resynchronization therapy (CRT) using left ventricular (LV) pacing in patients with severe heart failure, analyzing the impact of different anatomic locations for LV lead placement.
- A total of 120 patients were successfully implanted with LV leads, showing a significant reduction in implantation time over the study period and stable lead performance during follow-up, although the stimulation threshold increased slightly.
- Results indicated no major differences in LV lead performance based on the pacing site, with phrenic nerve stimulation occurring more frequently in one specific group, highlighting the importance of training for successful LV lead implantation.
Article Synopsis
- * Researchers analyzed 36 patients who were resistant to antiarrhythmic drugs, using advanced mapping and pacing techniques to target specific reentrant circuits for radiofrequency (RF) ablation.
- * Results showed a high success rate (94% for targeted tachycardias) with minimal complications, indicating that modern ablation techniques are effective and safe for these patients.